INCY · 10-Q · 2026Q3 · Full report

Research and Development Expense

INCYTE CORP · 2026-10-29 · Importance 85 · Surprise 82 · In source text

Research and development expense increased to $1.792 billion in the third quarter of 2026 from $506.6 million a year earlier, and to $2.825 billion for the first nine months from $1.439 billion. The increases include $1.2315 billion of acquired IPR&D expense related to Vega. Excluding that charge, higher clinical research and outside services expense reflected continued investment in late-stage development assets, while salary and benefits increased primarily because of higher headcount.

Key facts

• Research and development expenses for the three and nine months ended September 30, 2026 included $1.23 billion of expense for acquired in-process research and development assets from the Vega acquisition. source
• Incyte's salary and benefits-related research and development expense increased in the three and nine months ended September 30, 2026 compared with the corresponding 2025 periods, primarily due to increased headcount to sustain its development pipeline. source
• Clinical research and outside services expense increased in the three and nine months ended September 30, 2026 compared with the corresponding 2025 periods, primarily due to continued investment in late-stage development assets. source

Impact estimates